115 results on '"Suresh Babu, M."'
Search Results
2. Horizontal inequity in the utilisation of Continuum of Maternal Health care Services (CMHS) in India: an investigation of ten years of National Rural Health Mission (NRHM)
- Author
-
Gandhi, Sumirtha, Dash, Umakant, and Suresh Babu, M.
- Published
- 2022
- Full Text
- View/download PDF
3. Level of inequality and the role of governance indicators in the coverage of reproductive maternal and child healthcare services: Findings from India
- Author
-
Sumirtha Gandhi, Tulasi Malini Maharatha, Umakant Dash, and Suresh Babu M.
- Subjects
Medicine ,Science - Abstract
Background Diligent monitoring of inequalities in the coverage of essential reproductive, maternal, new-born and child health related (RMNCH) services becomes imperative to smoothen the journey towards Sustainable Development Goals (SDGs). In this study, we aim to measure the magnitude of inequalities in the coverage of RMNCH services. We also made an attempt to divulge the relationship between the various themes of governance and RMNCH indices. Methods We used National Family Health Survey dataset (2015–16) and Public Affairs Index (PAI), 2016 for the analysis. Two summative indices, namely Composite Coverage Index (CCI) and Co-Coverage (Co-Cov) indicator were constructed to measure the RMNCH coverage. Slope Index of Inequality (SII) and Relative Index of Inequality (RII) were employed to measure inequality in the distribution of coverage of RMNCH. In addition, we have used Spearman’s rank correlation matrix to glean the association between governance indicator and coverage indices. Results & conclusions Our study indicates an erratic distribution in the coverage of CCI and Co-Cov across wealth quintiles and state groups. We found that the distribution of RII values for Punjab, Tamil Nadu, and West Bengal hovered around 1. Whereas, RII values for Haryana was 2.01 indicating maximum inequality across wealth quintiles. Furthermore, the essential interventions like adequate antenatal care services (ANC4) and skilled birth attendants (SBA) were the most inequitable interventions, while tetanus toxoid and Bacilli Calmette- Guerin (BCG) were least inequitable. The Spearman’s rank correlation matrix demonstrated a strong and positive correlation between governance indicators and coverage indices.
- Published
- 2021
4. Follicular lymphoma transforming to DLBCL and reverting back to follicular lymphoma at relapse—a case report
- Author
-
Suresh Babu, M. C., Thottian, Antony George Francis, Lokanatha, D., Jacob, Linu Abraham, Lokesh, K. N., Rudresha, A. H., Rajeev, L. K., Smitha, Saldanha, Hassan, Syed Adil, Ashok, Khandare Pravin, Premalatha, C. S., and Suma, M. N.
- Published
- 2020
- Full Text
- View/download PDF
5. Does inequality hamper long run growth? Evidence from Emerging Economies
- Author
-
Suresh Babu, M., Bhaskaran, Vandana, and Venkatesh, Manasa
- Published
- 2016
- Full Text
- View/download PDF
6. Study of the noise in the magnetization data across the second magnetization peak and peak effect region in Ca3Rh4Sn13
- Author
-
Suresh Babu, M. and Pal, D.
- Published
- 2014
- Full Text
- View/download PDF
7. Step change in equilibrium magnetization across the second magnetization peak and the peak effect region of a weakly pinned low Tc superconductor, Ca3Rh4Sn13
- Author
-
Suresh Babu, M. and Pal, D.
- Published
- 2014
- Full Text
- View/download PDF
8. Price discovery and volatility spillovers in futures and spot commodity markets : Some Indian evidence
- Author
-
Kumar Mahalik, Mantu, Acharya, Debashis, and Suresh Babu, M.
- Published
- 2014
- Full Text
- View/download PDF
9. Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers—a Study from Indian Regional Cancer Centre
- Author
-
Smitha, C. S., Suresh, Babu M. C., Linu, J. A., Lakshmaiah, K. C., Govind, Babu K., Lokanatha, D., and Pretesh, R. K.
- Published
- 2017
- Full Text
- View/download PDF
10. Trends in regional industrial growth in India
- Author
-
Suresh Babu, M. and Rajesh Raj, S.N.
- Published
- 2011
- Full Text
- View/download PDF
11. Primary Gastrointestinal Mantle Cell Lymphoma: A Retrospective Study
- Author
-
Dasappa, Lokanatha, Suresh Babu, M. C., Sirsath, Nagesh T., Suresh, T. M., Govind Babu, K., Sathyanarayna, Vishwanatha, Lokesh, K. N., and Lakshmaiah, K. C.
- Published
- 2014
- Full Text
- View/download PDF
12. Study of Epicardial adipose tissue thickness in patients with Diabetes Mellitus and its correlation with severity of Coronary artery disease.
- Author
-
Sunil Kumar, S., Meghana, B.S., Suresh Babu, M., Desai, Nagaraj, Gona, Oliver Joel, Chalasani, Sri Harsha, and Pal, Nikita
- Published
- 2023
- Full Text
- View/download PDF
13. Study of Pulmonary Function Tests in Diabetic Nephropathy.
- Author
-
Ch., Ashrith, Suresh Babu, M., and C. S., Chetan
- Published
- 2022
14. Superconducting linear accelerator system for NSC
- Author
-
Prakash, P N, Datta, T S, Ajith Kumar, B P, Antony, J, Barua, P, Chacko, J, Choudhury, A, Chadhari, G K, Ghosh, S, Kar, S, Krishnan, S A, Kumar, Manoj, Kumar, Rajesh, Mandal, A, Mathuria, D S, Meena, R S, Mehta, R, Mistri, K K, Pandey, A, Suresh Babu, M V, Sahu, B K, Sarkar, A, Sonti, S S K, Rai, A, Venkatramanan, S, Zacharias, J, Bhowmik, R K, and Roy, A
- Published
- 2002
- Full Text
- View/download PDF
15. Clinical profile, cytogenetics and treatment outcomes of adult acute myeloid leukemia.
- Author
-
Namratha Udupa, M, Babu, K, Suresh Babu, M, Lakshmaiah, K, Lokanatha, D, Jacob, A, Lokesh, K, Rajeev, L, Rudresh, A, Devi, Lakshmi, Namratha Udupa, M S, Babu, K Govind, Suresh Babu, M C, Lakshmaiah, K C, Jacob, A Linu, Lokesh, K N, Rajeev, L K, and Rudresh, A H
- Subjects
ACUTE myeloid leukemia ,TREATMENT effectiveness ,BONE marrow ,CYTOGENETICS ,RETROSPECTIVE studies ,KARYOTYPES ,CHROMOSOME abnormalities - Abstract
Introduction and Aims: Acute myeloid leukemia (AML) in adults has poor prognosis. The epidemiologic profile of patients varies greatly in different geographic locations and so do the cytogenetic abnormalities and the FAB subtype of the AML. We intended to study the clinical profile, cytogenetics, and outcomes with standard of care treatment on our population in India.Methods: This was a retrospective study with systematic review of 203 case records. Primary objectives were to know the demographic profile of AML, prevalence of various FAB subtypes, cytogenetic abnormalities, and treatment outcomes at our center, which is a referral center of oncology. Two treatment outcomes considered in study for patients of AML were achievement of remission status of the bone marrow postintensive induction chemotherapy and sustenance of the remission for 6 months, once remission is achieved. Secondary objective was to study these outcomes in non-M3 AML in relation to cytogenetics.Results: Median age was 39 years. The most common FAB subtype observed was AML M2. About 65.6% patients achieved complete remission (CR), and 42.4% patients could sustain it for next 6 months. Cytogenetics correlated with prognosis but not age.Conclusions: Our population differs from the Western population regarding lower age, lower prevalence of adverse cytogenetics, and higher prevalence of favorable cytogenetic abnormalities. Cytogenetics had a good correlation with CR rates after chemotherapy as well as its sustenance. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Does sub-sectoral FDI matter for trade in emerging economies? Evidence from nonlinear ARDL approach.
- Author
-
Jithin, P. and Suresh Babu, M.
- Subjects
- *
REPAIR & maintenance services , *FOREIGN investments - Abstract
Using sectoral as well as subsectoral FDI data, we explore the asymmetric effect of nonfinancial services FDI on trade in services for 24 emerging economies for the period 1999–2016. We employ the panel unit root tests and recently developed panel nonlinear autoregressive distributed lag (NARDL) model, to analyze the impacts of FDI in service and its sub-sectors on trade in services. Our results confirm the nonlinear asymmetric relationship between nonfinancial services FDI and trade in services. We find that FDI in financial services has positive and significant impacts on trade in services, which implies there exists a complementary relationship between FDI in financial services and trade in services. Concurrently, positive changes in nonfinancial services FDI have adverse effects on trade in services in the long run, which indicates the substitutability of same with trade in services. Our results also show the complementary relationship between nonfinancial services FDI and manufacturing trade. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
17. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
- Author
-
Rudresha A. H., Chaudhuri, Tamojit, Lakshmaiah K. C., Babu, Govind K., Lokanatha D., Jacob, Linu Abraham, Suresh Babu M. C., Lokesh K. N., Rajeev L. K., Rudresha, A H, Lakshmaiah, K C, Lokanatha, D, Suresh Babu, M C, Lokesh, K N, and Rajeev, L K
- Subjects
METASTASIS ,RENAL cell carcinoma ,PROTEIN-tyrosine kinases ,HAND-foot syndrome ,PROGRESSION-free survival ,DRUG side effects ,HETEROCYCLIC compounds ,PROGNOSIS ,SULFONAMIDES ,UREA ,VITAMIN B complex ,INDOLE compounds ,PROTEIN kinase inhibitors ,SECONDARY primary cancer - Abstract
Background: Renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy, and historically a poor prognosis for metastatic disease has been reported, with a 5-year survival rate of <10%. Significant advances have been made in the last decade since the introduction of different tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and sorafenib. Unfortunately, even though the TKIs have been used for a long time, there are very few published data regarding the experience of TKI therapy in metastatic RCC (mRCC) from India.Materials and Methods: This is a single institutional review of mRCC patients treated between January 2012 and July 2017. Patients who received at least 1 month of first-line TKIs were included for analysis of response rates, toxicity, survival outcomes, and prognostic factors.Results: Of the 40 mRCC patients, 31 (77.5%) were males. Median age at diagnosis was 58 years (range: 38-80 years). The most common site of metastasis was lungs (n = 24) followed by bone (n = 19) and liver (n = 7). Three patients had favorable risk disease, whereas 25 had intermediate risk and 12 had poor risk disease according to the MSKCC risk criteria. First-line TKI therapy used was sunitinib in 24, pazopanib in 11, and sorafenib in 5 patients. Toxicities of TKIs were Grade 1 or 2 in 13 patients and Grade 3 or 4 in 9 patients; the most common being fatigue, followed by hand-foot syndrome, skin rash, mucositis, and hypertension. Overall, 29 patients (72.5%) had disease control (complete responses in 1, partial responses in 10, and stable disease in 18 patients), whereas 11 had progression of disease at initial evaluation. At a median follow-up of 16 months (range: 2-38 months), median progression-free survival (PFS) was 10.8 months and median overall survival was 19.1 months.Conclusions: Sunitinib and pazopanib are viable first-line options for mRCC and showed a comparable PFS in Indian patients. Careful patient selection, tailoring of TKI doses, and careful toxicity management are essential for optimum therapy. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
18. Acute Coronary Syndrome Manifesting as an Adverse Effect of All-trans-Retinoic Acid in Acute Promyelocytic Leukemia: A Case Report with Review of the Literature and a Spotlight on Management
- Author
-
Govind Babu, K., Lokesh, K. N., Suresh Babu, M. C., and Bhat, Gita R.
- Subjects
Article Subject ,organic chemicals ,neoplasms ,biological factors - Abstract
Background. Acute promyelocytic leukemia is characterized by t(15;17). This leads to the formation of PML/RARα which blocks the differentiation of blasts at the stage of promyelocytes. This is reversed by all-trans-retinoic acid (ATRA), a vitamin A derivative. Acute myocardial ischemia is a rare side effect of ATRA. Case Report. We report a case of acute coronary syndrome manifesting as an adverse effect of ATRA in a lady with APL who had no other risk factors for cardiovascular disease. Conclusions. We emphasize the need for high index of suspicion for the diagnosis of this entity. In the light of this case, the rare instances of ATRA associated acute myocardial ischemia recorded in the literature and the options available for treatment of acute promyelocytic leukemia sans ATRA have been reviewed.
- Published
- 2016
- Full Text
- View/download PDF
19. Novel approach towards one pot stereospecific synthesis of carbohydrate derived substituted imidazolines
- Author
-
Gautam, Vibha, Kagita, Veera Babu, Nambiar, Sudhir, Phaneendra, Gutala, Manjunatha, Sulur G., Ramasubramanian, Sridharan, Suresh Babu, M., Keshwan, Jaikumar, Bhagat, Sagar, Prakash, Ravindran, and Puranik, Ramachandra
- Published
- 2014
- Full Text
- View/download PDF
20. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
- Author
-
Lakshmaiah K. C., Chaudhuri, Tamojit, Babu, Govind K., Dasappa, Lokanatha, Jacob, Linu Abraham, Suresh Babu M. C., Rudresha A. H., Lokesh K. N., Rajeev L. K., Lakshmaiah, K C, Lokanatha, Dasappa, Suresh Babu, M C, Rudresha, A H, Lokesh, K N, and Rajeev, L K
- Subjects
COLON cancer ,CANCER chemotherapy ,ARSENIC trioxide ,TOXICITY testing ,ANTINEOPLASTIC agents ,ARSENIC compounds ,CAMPTOTHECIN ,COLON tumors ,DRUG resistance in cancer cells ,FLUOROURACIL ,FOLINIC acid ,LIVER tumors ,METASTASIS ,OXIDES ,PERITONEUM ,RECTUM tumors - Abstract
Background: After failing oxaliplatin-based first-line chemotherapy (CT), approximately 4%-21% of patients with metastatic colorectal cancer (mCRC) respond to irinotecan-based second-line treatment. Earlier studies have demonstrated that arsenic trioxide (ATO) can significantly resensitize resistant colon cancer to 5-fluorouracil (5-FU) by downregulating thymidylate synthase (TS). We hypothesized that a combination of ATO with infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) regimen in mCRC patients refractory to first-line FOLFOX/CAPOX could further improve the outcome of second-line CT.Materials and Methods: Patients were administered ATO 0.15 mg/kg/day on days 1-2 along with FOLFIRI regimen at standard doses every 2 weeks, until disease progression, unacceptable toxicity, or patients' refusal. Responses to CT were reported according to RECIST 1.1. Adverse events were classified based on CTCAE version 4.0.Results: Between September 2016 and July 2017, 17 patients with refractory mCRC were treated with this investigational combination. The median age was 49 years; 13 males and 4 females; ECOG PS 0-1/2, 14/3. The most common site of metastases was liver (n = 11) followed by peritoneum (n = 7) and number of involved metastatic sites 1-2/≥3, 9/8. After 6 cycles of CT, overall response rate and disease control rate were 17.6% and 82.4%, respectively (complete remission = 0, partial remission = 3 patients, stable disease = 11 patients). Median progression-free survival was 5.3 months (95% confidence interval [CI]: 4.3-7.0) and median overall survival was 9 months (95% CI: 7.4-10.5) from the initiation of ATO plus FOLFIRI. The toxicities were as follows: Grade 1/2 toxicity: fatigue (7 patients), constipation (2), and nausea and vomiting (2); Grade 3 toxicity: fatigue (3), neutropenia (2), febrile neutropenia (1), diarrhea (2), and QTc prolongation (1). No patient experienced Grade 4 toxicities.Conclusions: The addition of ATO to FOLFIRI regimen as second-line CT in patients with refractory mCRC offered an encouraging antitumor effect at the cost of manageable toxicity. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
21. Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma in adults: Results from a nonendemic region.
- Author
-
Lokesh, K. N., Chaudhuri, Tamojit, Lakshmaiah, K. C., Babu, K. Govind, Lokanatha, D., Jacob, Linu A., Babu, M. C. Suresh, Rudresha, A. H., Rajeev, L. K., and Suresh Babu, M C
- Subjects
CANCER chemotherapy ,NASOPHARYNX cancer ,CISPLATIN ,RADIOTHERAPY ,DOCETAXEL - Abstract
Background: Recently published prospective clinical trials and two meta-analyses have shown that addition of induction chemotherapy (IC) to concurrent chemoradiation (CRT) could potentially improve outcomes in comparison to CRT alone, in locoregionally advanced nasopharyngeal carcinoma (LANPC). Although it remains unclear which is the best IC regimen to be offered and for how many cycles. Unfortunately, till date, there are no published data from India regarding the outcomes of various commonly used IC regimens before CRT, in LANPC.Materials and Methods: Patients diagnosed with LANPC from January 2012 to December 2017, who received three cycles of IC before definitive CRT were reviewed retrospectively. Patients' profile, toxicity of IC, response rates, failure-free survival, and overall survival (OS) were evaluated.Results: A total 34 patients with LANPC who received IC were reviewed. The median age at diagnosis was 36 years, and the majority were males (67.6%, n = 23). Nineteen patients received IC with paclitaxel plus cisplatin regimen (TP) and the remaining 15 patients received IC with docetaxel/paclitaxel plus cisplatin plus 5-FU regimen (TPF). The overall response rates after three cycles of TP and TPF IC were 68.4% and 80%, respectively, and the corresponding rates were 84.2%and 93.3%, respectively, 2 months after completion of CRT. At a median follow-up of 24 months, 2-year failure-free survival and OS for TP arm were 78.9% and 89.5%, and the corresponding rates for TPF arm were 86.7% and 93.3%, respectively. All Grade III-IV toxicities were numerically higher with triplet IC regimen in comparison to doublet regimen.Conclusion: In this retrospective analysis, there was no significant difference between taxane-based doublet and triplet IC regimens, in terms of survival outcomes, although Grade III-IV toxicities were numerically higher with triplet IC regimen. Clearly, these hypothesis-generating findings should be tested in a prospective randomized setting. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
22. Primary breast angiosarcoma – a single institution experience from a tertiary cancer center in South India.
- Author
-
Lokanatha, D., Anand, Abhishek, Lakshmaiah, K. C., Govind Babu, K., Jacob, Linu Abraham, Suresh Babu, M. C., Lokesh, K. N., Rudresha, A. H., Rajeev, L. K., Saldanha, Smitha C., Giri, G. V., Koppaka, Deepak, and Kumar, Rekha V.
- Subjects
ANGIOSARCOMA ,TRABECTEDIN ,RADIATION ,CANCER chemotherapy ,PROGNOSIS - Abstract
Introduction: Primary angiosarcoma of the breast is a rare entity with incidence of less than 0.05% of all malignant breast neoplasms. It occurs in young females without any associated risk factors. The tumor behaves aggressively and has a poor prognosis compared to invasive ductal carcinoma. Method: It was a retrospective observational study done at a tertiary cancer center from January 2012 to December 2016. The medical records of patients diagnosed with primary breast angiosarcoma were reviewed for the study. Clinicopathological profile, treatment, and the outcomes were analyzed. Results: Four patients were diagnosed with primary breast angiosarcoma out of 2560 breast cancer patients seen over a period of 5 years. Two had metastatic disease at presentation. Among four patients, two underwent surgery of the primary tumor, whereas, all received chemotherapy either as adjuvant or palliative setting. One patient received adjuvant radiation therapy. Three patients received 2nd line and one received 3rd line chemotherapy on disease progression. After a median follow-up of 18 months one patient was surviving on 3rd line chemotherapy with trabectedin. Other three succumbed to disease after progression. Conclusion: Due to a small number of this malignancy randomized studies are difficult to perform and optimum treatment strategy still need to be defined. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
23. First-line tyrosine kinase inhibitors in metastatic renal cell carcinoma: A regional cancer center experience.
- Author
-
Rudresha, A, Chaudhuri, Tamojit, Lakshmaiah, K, Babu, Govind, Lokanatha, D, Jacob, Linu, Suresh Babu, M, Lokesh, K, and Rajeev, L
- Subjects
PROTEIN-tyrosine kinase inhibitors ,RENAL cell carcinoma ,SORAFENIB ,SURGICAL complications ,FATIGUE (Physiology) ,HAND-foot syndrome - Abstract
BACKGROUND: Renal cell carcinoma (RCC) is highly resistant to systemic chemotherapy, and historically a poor prognosis for metastatic disease has been reported, with a 5-year survival rate of <10%. Significant advances have been made in the last decade since the introduction of different tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, and sorafenib. Unfortunately, even though the TKIs have been used for a long time, there are very few published data regarding the experience of TKI therapy in metastatic RCC (mRCC) from India. MATERIALS AND METHODS: This is a single institutional review of mRCC patients treated between January 2012 and July 2017. Patients who received at least 1 month of first-line TKIs were included for analysis of response rates, toxicity, survival outcomes, and prognostic factors. RESULTS: Of the 40 mRCC patients, 31 (77.5%) were males. Median age at diagnosis was 58 years (range: 38–80 years). The most common site of metastasis was lungs (n = 24) followed by bone (n = 19) and liver (n = 7). Three patients had favorable risk disease, whereas 25 had intermediate risk and 12 had poor risk disease according to the MSKCC risk criteria. First-line TKI therapy used was sunitinib in 24, pazopanib in 11, and sorafenib in 5 patients. Toxicities of TKIs were Grade 1 or 2 in 13 patients and Grade 3 or 4 in 9 patients; the most common being fatigue, followed by hand-foot syndrome, skin rash, mucositis, and hypertension. Overall, 29 patients (72.5%) had disease control (complete responses in 1, partial responses in 10, and stable disease in 18 patients), whereas 11 had progression of disease at initial evaluation. At a median follow-up of 16 months (range: 2–38 months), median progression-free survival (PFS) was 10.8 months and median overall survival was 19.1 months. CONCLUSIONS: Sunitinib and pazopanib are viable first-line options for mRCC and showed a comparable PFS in Indian patients. Careful patient selection, tailoring of TKI doses, and careful toxicity management are essential for optimum therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
24. Induction Chemotherapy in Technically Unresectable Locally Advanced T4a Oral Cavity Squamous Cell Cancers: Experience from a Regional Cancer Center of South India.
- Author
-
Rudresha, A. H., Chaudhuri, Tamojit, Lakshmaiah, K. C., Govind Babu, K., Dasappa, Lokanatha, Abraham Jacob, Linu, Suresh Babu, M. C., Lokesh, K. N., and Rajeev, L. K.
- Subjects
CANCER cells ,CANCER treatment ,DISEASE progression ,CANCER chemotherapy ,SQUAMOUS cell carcinoma - Abstract
Objectives: The present study aimed to investigate the efficacy, toxicity, and impact of induction chemotherapy (IC) in technically unresectable T4a oral cavity squamous cell cancers (OSCCs). Materials and Methods: Patients diagnosed with technically unresectable locally advanced T4a OSCC from January 2013 and November 2016 at our center, who received 2-3 cycles of IC and then assessed for resectability, were reviewed retrospectively. Patients' profile, response rates and toxicity of IC, resectability status, and overall survival (OS) were evaluated. Statistical analyses were performed using SPSS version 17.0 for Windows (SPSS Inc., Chicago, IL, USA). Results: Totally 80 patients received IC, and of them 58 (72.5%) were males. Median age at diagnosis was 44 years (range, 34-62 years). All our patients received IC with doublet regimen. Majority of the patients had buccal mucosa cancers (73.8%), followed by gingivobuccal complex (21.2%) and oral tongue (5%) primaries. After IC, partial response was achieved in 17 (21.3%) patients, stable disease in 49 (61.3%) patients and disease progression was noted in 14 (17.4%) patients. Post-IC, resectability was achieved in 19 (23.8%) of 80 patients, but 4 of them did not undergo surgery due to logistic and personal reasons. The median OS of patients who underwent surgery followed by adjuvant local therapy (n = 15) was 16.9 months (95% CI: 15.2-19.8 months) and for those treated with nonsurgical local therapy (n = 65) was 8.8 months (95% CI: 6.8-10.6 months) (log-rank P = 0.000). Conclusions: IC had a manageable toxicity profile and achieved resectability in 23.8% of our patients with technically unresectable T4a OSCC. Patients underwent resection had a significantly better median OS than those who received nonsurgical local treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
25. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
- Author
-
Lokesh, K. N., Chaudhuri, Tamojit, Lakshmaiah, K. C., Babu, K. Govind, Dasappa, Lokanatha, Jacob, Linu Abraham, Babu, Suresh M. C., Rudresha, A. H., Rajeev, L. K., and Suresh Babu, M C
- Subjects
LIVER cancer -- Etiology ,ETIOLOGY of cancer ,LIVER cancer patients ,LIVER disease treatment ,CHEMOEMBOLIZATION - Abstract
Background: Hepatocellular carcinoma (HCC) is a major health burden and the seventh most common cause of cancer-related death in India. Patients with advanced unresectable HCC have a poor prognosis with a reported median survival of only 2-3 months with the best supportive care (BSC). Sorafenib is the only drug that has demonstrated a survival benefit over BSC in advanced HCC. Unfortunately, even though it has been used for a long time, there are very few published data regarding the experience of sorafenib therapy in advanced HCC from India.Materials and Methods: Patients diagnosed with advanced HCC from January 2012 to July 2017 at our center were reviewed retrospectively. Patients' profile, time to progression, survival, and toxicity of sorafenib therapy were evaluated.Results: Of the 48 advanced patients with HCC, 35 (72.9%) were male. The median age at diagnosis was 52 years. The most common presenting symptom was abdominal pain (77%, n = 37), followed by abdominal distension (37.5%, n = 18), loss of appetite and/or weight (33.3%, n = 16), and jaundice (16.7%, n = 8). Hepatitis B virus infection was documented in 37 patients (77%), whereas 4 patients had hepatitis C virus infection. Patients were treated with standard dose sorafenib (n = 30), BSC alone (n = 14), or transarterial chemoembolization followed by sorafenib (n = 4). Sorafenib therapy was well-tolerated in most cases. The median progression-free survival with upfront sorafenib was 4.3 months. The median overall survival (OS) of the patients who received upfront sorafenib was significantly better than those treated with BSC alone (5.9 vs 3.0 months; log-rank P= 0.00).Conclusion: Sorafenib therapy was well-tolerated and provided about 3 months longer median OS in our patients with advanced HCC than those treated with BSC alone. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
26. Colorectal cancer presenting as bone metastasis.
- Author
-
Babu, M. C. Suresh, Garg, Sunny, Lakshmaiah, K. C., Babu, K. Govind, Kumar, Rekha V., Loknatha, D., Abraham, Linu Jacob, Rajeev, L. K., Lokesh, K. N., Rudresha, A. H., Rao, Suparna Ajit, and Suresh Babu, M C
- Subjects
COLON cancer ,CARCINOEMBRYONIC antigen ,TUMORS ,CANCER chemotherapy ,METASTASIS ,AGE distribution ,BONE tumors ,COLON tumors ,HUMAN reproduction ,PROGNOSIS ,RECTUM tumors ,TUMOR antigens ,KAPLAN-Meier estimator - Abstract
Introduction: Bone metastasis is a rare site of metastasis, seen in only 3.7-11% of clinical cases. Isolated bone involvement has been reported very rarely in literature. Moreover, the patients who have bone metastasis at presentation are even rare.Objectives: To discuss the demographic characteristics, carcinoembryonic antigen (CEA) levels, pattern of bone involvement, and their correlation with survival in patients of colorectal cancer that have bone metastasis at the time of presentation.Materials and Methods: Retrospectively, tumor registry was analyzed for the cases of colorectal cancer presenting with bone metastasis between 2008 and 2013. Survival curves were generated by Kaplan-Meier method and analyzed using the log-rank test.Results: Ten such patients were identified (male:female = 7:3) of the total 410 patients. Median age was 41 years (22-50 years). All patients were Conclusions: In this study, the patients of colorectal cancer presenting with bone metastasis were of male sex and younger age. The factors that were associated with reduced survival were extraosseous and liver involvement. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
27. Induction chemotherapy in locally advanced T4b oral cavity squamous cell cancers: A regional cancer center experience.
- Author
-
Rudresha, A. H., Chaudhuri, T., Lakshmaiah, K. C., Babu, K. G., Dasappa, L., Jacob, L. A., Suresh Babu, M. C., Lokesh, K. N., and Rajeev, L. K.
- Subjects
CANCER chemotherapy ,ORAL cancer ,SQUAMOUS cell carcinoma ,DISEASE progression ,ANTINEOPLASTIC agents ,HEAD tumors ,MOUTH tumors ,NECK tumors ,RETROSPECTIVE studies - Abstract
Objectives: The present study aimed to investigate the efficacy, toxicity, and impact of induction chemotherapy (IC) in locally advanced T4b oral cavity squamous cell cancers (OSCCs).Materials and Methods: Patients diagnosed with locally advanced T4b OSCC from January 2013 to October 2016 at our center, who received 2-3 cycles of IC and then assessed for resectability, were reviewed retrospectively. Patients' profile, response, and toxicity of IC, resectability status, and overall survival (OS) were evaluated. Statistical analyses were performed by SPSS software version 17.Results: A total of 116 patients received IC, and out of them 90 (77.6%) were males. Median age at diagnosis was 43 years (range 31-62 years). Nearly 103 (88.8%) of our patients received doublet chemotherapy and the rest of the patients received triplet regimen. Majority of the patients had buccal mucosa cancers (71.6%), followed by gingivobuccal complex (21.6%) and oral tongue (6.9%) primaries. After IC, partial response was achieved in 20 (17.3%) patients, stable disease in 68 (58.6%) patients, and disease progression was noted in 28 (24.1%) patients. Post-IC, resectability was achieved in 22 (19%) of 116 patients, but 6 of them did not undergo surgery due to logistic and personal reasons. The median OS of patients who underwent surgery followed by adjuvant local therapy (n = 16) was 19.7 months (95% confidence interval [CI]: 16.0-22.8 months) and for those treated with nonsurgical local therapy (n = 100) was 7.1 months (95% CI: 5.8-8.2 months) (log-rank P = 0.000).Conclusions: IC had a manageable toxicity profile and achieved resectability in 19% of our patients with T4b OSCC. Patients underwent resection had a significantly better median OS than those who received nonsurgical local treatment. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
28. BCL2 and Subtype as Prognostic and Predictive Markers of Diffuse Large B-cell Lymphoma.
- Author
-
Lakshmaiah, K. C., Govind Babu, K., Dasappa, Loknatha, Abraham, Linu Jacob, Suresh Babu, M. C., Premalatha, C. S., Rao, Clementina Rama, Rajeev, L. K., Rudresha, A. H., Lokesh, K. N., Rao, Suparna Ajit, and Garg, Sunny
- Subjects
BCL-2 proteins ,BIOMARKERS ,LYMPHOMAS ,IMMUNOHISTOCHEMISTRY ,GERMINAL centers ,PROGNOSIS - Abstract
Introduction: Since patients with similar International Prognostic Index scores have varied outcomes, molecular signatures, including BCL2 overexpression have been studied to prognosticate diffuse large B-cell lymphoma (DLBCL), which have shown varied outcomes. Objective: The aim of this study is to correlate BCL2 protein expression with survival in two biologic subgroups of DLBCL. Materials and Methods: A total of 112 adults with DLBCL between 2008 and 2012 were identified. BCL2 overexpression was determined using immunohistochemistry. Results: Median survival was greater in BCL2 negative (n = 52) than positive (n = 44) (36 vs. 24.5 months; P = 0.003). In nongerminal center B-cell type (NGCB), BCL2 negativity had a survival advantage over BCL2 positive (36.5 vs. 17 months; P = 0.02), similarly in GCB (36 vs. 33 months; P = 0.032). Of 109, 66 received CHOP and 43 R-CHOP. R-CHOP arm had a significant survival advantage over CHOP arm (38 vs. 24 months; P < 0.05). In CHOP group, GCB had a survival advantage over NGCB (32 vs. 14 months; P < 0.05). In R-CHOP group, no significant difference was seen. BCL2 negativity had a survival advantage in CHOP (31 vs. 20.5 months; P < 0.05) as well as R-CHOP group (39 vs. 26.5 months; P < 0.05). Analysis was performed in each treatment arm (CHOP and RCHOP) based on BCL2 expression (positive or negative) in GCB and NGCB arms. No statistically significant difference was seen in the four arms. Conclusions: BCL2 although an indicator of poor outcome, its use to predict outcomes alone in the absence of study of the expression of concomitant markers, such as myc/BCL6 would cause a bias in results. Furthermore, its relevance in the rituximab era needs further validation. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Pattern of Bone Marrow Involvement by Solid Tumors: Experience from a Tertiary Care Center from South India.
- Author
-
Rudresha, A. H., Patidar, Rajesh, Lakshmaiah, Kuntegowdanahalli C., Babu, K. Govind, Lokanatha, Dasappa, Jacob, Linu Abraham, Suresh Babu, M. C., Namrata, N. R., Kadabur, N. Lokesh, Rajeev, L. K., Anand, Abhishek, and Asati, Vikas
- Subjects
BONE marrow ,NEUROBLASTOMA ,EWING'S sarcoma ,BONE marrow cancer ,BONE marrow examination ,TERTIARY care ,NEEDLE biopsy - Abstract
Background: Bone marrow involvement by solid tumor implicates advanced disease and dismal prognosis. Bone marrow aspiration and biopsy are routinely performed as staging workup for certain small round cell tumors and also for unexplained cytopenia in other solid tumors. It is important to rule out bone marrow involvement before planning for curative treatment. Materials and Methods: This was a retrospective observational study. The aim of our study was to evaluate the pattern of bone marrow involvement by different solid tumors and their correlation with the hematological abnormalities. We retrospectively evaluated bone marrow aspirations and biopsy performed in past 3 years. Results: At our institution, bone marrow examinations were performed in 440 patients during past 3 years for solid malignancies. Out of 440, 206 were pediatric cases and 234 were adult cases. Bone marrow was involved in 56 (12.7%) patients. Among the pediatric cases, bone marrow involvement was present in 30 (12.8%) cases, and in adult cases, bone marrow was involved was in 26 (11.1%) cases. Neuroblastoma (40%) was the most common malignancy, which involved the bone marrow among pediatric cases, followed by retinoblastoma (26.6%) and Ewing’s sarcoma (20%). Among adult patients, neuroendocrine carcinoma (23%) was at the top of the list of tumors involving bone marrow, which is followed by Ewing’s sarcoma (19.2%) and nasopharyngeal carcinoma (11.5%). Conclusion: Neuroblastoma and neuroendocrine carcinoma are the major cause of bone marrow involvement among the solid malignancies in pediatric and adult population, respectively. Use of immunohistochemistry markers on bone marrow biopsies may result in higher detection rate. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
30. A case series of patients with de novo Philadelphia-positive acute myeloid leukemia at a tertiary care center in South India - clinical profile, outcomes, and review of literature.
- Author
-
Loknatha, D., Rao, Suparna Ajit, Lokesh, K. N., Govind Babu, K., Suresh Babu, M. C., and Lakshmaiah, K. C.
- Published
- 2016
- Full Text
- View/download PDF
31. Enantioselective Synthesis of ((1 R ,2 R )-Cyclohexane-1,2-diyl)bis(methylene)dimethanesulfonate, a Lurasidone Hydrochloride Intermediate.
- Author
-
Ravi Ganesh, K., Pachore, Sharad S., Pratap, T. V., Umesh, K., Basaveswara Rao, M. V., Murthy, C., and Suresh Babu, M.
- Subjects
ENANTIOSELECTIVE catalysis ,SULFONATES ,CYCLOHEXANE synthesis ,CHLORIDES ,INTERMEDIATES (Chemistry) ,EPIMERIZATION ,ANTIPSYCHOTIC agents - Abstract
A concise, economical, and highly enantioselective synthesis of bismesylate intermediate of lurasidone HCl, an antipsychotic, has been developed. The key steps involved in the synthesis are thionyl chloride–catalyzed esterification of tetrahydrophthalic anhydride in MeOH, epimerization ofcistotransisomer, hydrolysis of the diester, resolution of the diacid, reduction with Red-Al, and finally bismesylation of the corresponding diol, which provided the desired intermediate ((1 R,2 R)-cyclohexane-1,2-diyl)bis(methylene) dimethanesulfonate in overall good yield. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
32. Outcome of young adults with chronic myeloid leukemia treated with upfront imatinib: A single institutional experience.
- Author
-
Govind Babu K, Thanky, Aditi, Jacob, Linu Abraham, Suresh Babu M. C., Dasappa, Loknatha, and Ganguly, Sandip
- Published
- 2015
- Full Text
- View/download PDF
33. DISCOVERY OF A NEW SUB-POPULATION, MAPPING AND UPDATED RED LIST ASSESSMENT OF THE ENDANGERED CYCAS BEDDOMEI DYER (CYCADALES: CYCADACEAE).
- Author
-
Ravi Prasad Rao, B., Chennakesavulu Naik, M., Salamma, S., Suresh Babu, M. V., and Rasingam, L.
- Subjects
CYCAS ,CYCADACEAE ,ENDANGERED species - Abstract
A new sub-population of Cycas beddomei Dyer (Cycadaceae), hitherto believed to be endemic to the Seshachalam Hills (Tirupati-Kadapa Hills) of Andhra Pradesh is discovered from Velikonda Hills (Nellore-Kadapa districts) of Andhra Pradesh. Hence its global distribution status is hereby revised endemic to Seshachalam and Velikonda hills of Eastern Ghats of Andhra Pradesh. Combined datasets of our earlier studies with the latest indicated no change in its 'Endangered' status. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
34. Safety and antitumor activity of arsenic trioxide plus infusional 5-fluorouracil, leucovorin, and irinotecan as second-line chemotherapy for refractory metastatic colorectal cancer: A pilot study from South India.
- Author
-
Lakshmaiah, K, Chaudhuri, Tamojit, Babu, Govind, Lokanatha, Dasappa, Jacob, Linu, Suresh Babu, M, Rudresha, A, Lokesh, K, and Rajeev, L
- Subjects
COLON cancer treatment ,ARSENIC trioxide ,CANCER chemotherapy ,OXALIPLATIN ,FOLINIC acid ,FLUOROURACIL - Abstract
BACKGROUND: After failing oxaliplatin-based first-line chemotherapy (CT), approximately 4%–21% of patients with metastatic colorectal cancer (mCRC) respond to irinotecan-based second-line treatment. Earlier studies have demonstrated that arsenic trioxide (ATO) can significantly resensitize resistant colon cancer to 5-fluorouracil (5-FU) by downregulating thymidylate synthase (TS). We hypothesized that a combination of ATO with infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) regimen in mCRC patients refractory to first-line FOLFOX/CAPOX could further improve the outcome of second-line CT. MATERIALS AND METHODS: Patients were administered ATO 0.15 mg/kg/day on days 1–2 along with FOLFIRI regimen at standard doses every 2 weeks, until disease progression, unacceptable toxicity, or patients' refusal. Responses to CT were reported according to RECIST 1.1. Adverse events were classified based on CTCAE version 4.0. RESULTS: Between September 2016 and July 2017, 17 patients with refractory mCRC were treated with this investigational combination. The median age was 49 years; 13 males and 4 females; ECOG PS 0–1/2, 14/3. The most common site of metastases was liver (n = 11) followed by peritoneum (n = 7) and number of involved metastatic sites 1–2/≥3, 9/8. After 6 cycles of CT, overall response rate and disease control rate were 17.6% and 82.4%, respectively (complete remission = 0, partial remission = 3 patients, stable disease = 11 patients). Median progression-free survival was 5.3 months (95% confidence interval [CI]: 4.3–7.0) and median overall survival was 9 months (95% CI: 7.4–10.5) from the initiation of ATO plus FOLFIRI. The toxicities were as follows: Grade 1/2 toxicity: fatigue (7 patients), constipation (2), and nausea and vomiting (2); Grade 3 toxicity: fatigue (3), neutropenia (2), febrile neutropenia (1), diarrhea (2), and QTc prolongation (1). No patient experienced Grade 4 toxicities. CONCLUSIONS: The addition of ATO to FOLFIRI regimen as second-line CT in patients with refractory mCRC offered an encouraging antitumor effect at the cost of manageable toxicity. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
35. Anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL) of breast in a patient without a breast implant.
- Author
-
Sathyanarayanan, Vishwanath, Lokesh, Kadabur Nagendrappa, K. C., Lakshmaiah, K., Govind Babu, D., Lokanatha, C., Suresh Babu M., Rao, Clementina Rama, and Chennagiri, Premalata
- Published
- 2014
- Full Text
- View/download PDF
36. Multiple myeloma: Experience of an institute in limited resource setting.
- Author
-
Jacob, Linu Abraham, Babu, M. C. Suresh, Lakshmaiah, K. C., Babu, K. Govind, Lokanatha, D., Rajeev, L. K., Lokesh, K. N., Rudresha, A. H., Agarwal, Ankit, Gar, Sunny, Suresh Babu, M C, and Garg, Sunny
- Subjects
MULTIPLE myeloma ,B cell lymphoma ,MULTIPLE myeloma diagnosis ,MULTIPLE myeloma treatment ,PLASMA cells ,AUTOTRANSPLANTATION ,PATIENTS ,ANTINEOPLASTIC agents ,HEMATOPOIETIC stem cell transplantation ,PROGNOSIS ,TREATMENT effectiveness ,KAPLAN-Meier estimator ,ECONOMICS - Abstract
Introduction: Multiple myeloma (MM) is a plasma cell dyscrasias and an incurable clonal B-cell malignancy, with an annual incidence of 1% of all malignancies. The mainstay of treatment of myeloma is induction treatment followed by consolidation with autologous stem cell transplant (ASCT). However, still in a developing country like India where affordability is a major hurdle for health care, a number of MM patients are not able to undergo ASCT.Aim: To study the epidemiological features and outcome of MM patients treated in a limited resource setting.Materials and Methods: We conducted a retrospective study at our institute to identify patients diagnosed as MM from 2005 to 2016. We studied the epidemiological profile and the outcome of the treatment in terms of response rates and overall survival.Statistical Analysis: Survival analysis was performed using Kaplan-Meier curve.Results: Median age at diagnosis is 54 years (range: 39-85 years). IgG myeloma was the most common type seen in 72% of patients. The International Staging System (ISS) was ISS I (31%), ISS II (30%), and ISS III (39%). The median duration of treatment for thalidomide + dexamethasone (TD) and bortezomib + TD (VTD) was 9 and 7 months, respectively. Median survival for the TD versus VTD regimen (in a nontransplant setting) for the ISS I, ISS II, and ISS III groups was 49 and 55 months (P = 0.056), 42 and 48 months (P < 0.05), 21 and 27 months (P < 0.05), respectively.Conclusion: Proteasome inhibitors significantly improved the median survival for patients with MM (ISS II and ISS III) treated in a limited resource setting. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
37. Plasmablastic lymphoma: Does prognosis differ with HIV status and site of disease?
- Author
-
Govind babu, K., Suresh Babu, M. C., Abraham, Linu Jacob, Suresh, T. M., Dasappa, Lokanatha, Sirsath, Nagesh T., and Lakshmaiah, Kuntejowdahalli C.
- Abstract
Background: Apart from its common occurrence in the oral cavity in HIV-positive patients, plasmablastic lymphoma (PBL) has also been described at extraoral sites and among immunocompetent individuals. There is sparse data quoting prognostication of PBL depending on the site of occurrence and HIV status of patients. Aims: The present study was carried out at a tertiary oncology center to address the issue whether PBLs occurring at oral and extraoral sites differ prognostically and whether HIV status of patient has any impact on prognosis. Materials and Methods: This was a retrospective observational study conducted at our center on consecutive patients diagnosed with PBL, from January 2008 to December 2012. Results: We had four patients with oral PBL; three male and one female. Sites of involvement were oral tongue and buccal mucosa. Two patients died within 6 months of diagnosis due to disease progression while on treatment. One patient was lost to follow-up after achieving complete remission (CR) after chemotherapy. Only one patient completed the prescribed schedule of chemotherapy and radiotherapy and is in CR with 33 months follow-up. There were four extraoral PBL patients; three female and one male. Extraoral sites were ileocaecal region, ovary, clavicle and rectum. Three patients died within 6 months due to progressive disease during treatment. Only one patient has completed chemotherapy and is in CR with 18 months follow-up. Among all these eight oral and extraoral PBL patients, four were HIV positive. Two of them are in CR after treatment (18 months and 33 months follow-up). One patient died during treatment and one patient was lost to follow-up after being in CR. Unfortunately, none of the other four HIV-negative patients could survive for more than 6 months after diagnosis. Conclusion: Both oral and extraoral PBLs have aggressive clinical course and an overall unfavorable outcome. Prognosis of HIV-associated PBL seems to be better with addition of highly active antiretroviral therapy to chemotherapy. Further large sample studies are needed to confirm these results. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
38. School Teacher's Knowledge Regarding Dental Health.
- Author
-
Sai Sankar, A. J., Sreedevi, E., Suresh Babu, M., Naveen, V., and Rajavardhan, K.
- Subjects
CHILDREN'S dental care ,PEDIATRIC oral medicine ,DENTAL health education ,TREATMENT of dental caries ,DECIDUOUS dentition (Tooth development) ,DENTAL education - Abstract
The seeds of prevention should be sown early in the life to have its benefits in evidence. When it comes to the pediatric age group the information delivered by the school teachers will have better impact. With this background in the mind the survey was designed to assess the school teachers' knowledge regarding dental aspects and also to make them aware about their indispensible role as oral health messengers. The survey contained questions related to their knowledge about dentition, exposure to dental health education, awareness on caries, experience and knowledge on providing first-aid in instances of dental trauma. A total of 850 school teachers were selected from rural and urban areas in and around Guntur city and the questionnaire was distributed. When answers obtained were summarized it was found that the overall knowledge of school teachers regarding the above mentioned dental aspects was relatively low which gives an alarming signal to improvise the knowledge of school teachers. This survey was an effort to interact with the teachers so that the knowledge, attitude and practice of the teachers regarding dental issues can be identified. Thus few recommendations were suggested to achieve the goal. [ABSTRACT FROM AUTHOR]
- Published
- 2013
39. Liberalization, Market Power, and Productivity Growth in Indian Industry.
- Author
-
Balakrishnan, Pulapre, Parameswaran, M., Pushpangadan, K., and Suresh Babu, M.
- Subjects
INDUSTRIAL policy ,COMMERCIAL policy ,INDUSTRIAL productivity ,TRADE regulation ,ECONOMETRICS ,BUSINESS enterprises - Abstract
Using firm-level panel data we investigate whether reform of the trade and industrial policy regimes in India introduced in 1991 resulted in a reduction in market power and/or an acceleration in productivity growth, consequences that have been predicted in theory. Econometric testing of the theory for every industry group at the two-digit level in India yielded limited evidence of acceleration in productivity growth and no evidence of a reduction in market power. This is interpreted as suggesting that in the case of Indian industry trade liberalization has not exhibited the potential often attributed to it. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
40. Spontaneous perforation of the cystic duct.
- Author
-
Suresh-Babu, Mirajkar V., Thomas, Adrian G., Miller, Victor, Dickson∗, Alan, Suresh-Babu, M V, Thomas, A G, Miller, V, and Dickson, A
- Published
- 1998
41. Plasma cell leukemia: Single institution experience.
- Author
-
Babu, K. Govind, Jacob, Linu Abraham, Agarwal, Ankit, Lakshmaiah, K. C., Lokanatha, D., Babu, M. C. Suresh, Rajeev, L. K., Lokesh, K. N., Rudresha, A. H., and Suresh Babu, M C
- Subjects
PLASMA cell leukemia ,MONOCLONAL gammopathies ,PLASMA cells ,STEM cell transplantation ,IMMUNOMODULATORS ,TREATMENT effectiveness ,RETROSPECTIVE studies - Abstract
Background: The first case of plasma cell leukemia (PCL) was recognized by Gluzinski and Reichentein. It is the most aggressive among the monoclonal gammopathies. It is diagnosed by the presence of more than 20% plasma cells in the peripheral blood or an absolute plasma cell count of> 2000/mm3. Because of the relatively low incidence, most data come from case reports and retrospective studies. No prospective series have been published, and only seven reports including more than twenty patients have been identified. We report a retrospective series of 18 patients identified as PCL.Aim: To study the clinical features and outcome of patients with PCL.Materials and Methods: A retrospective study was conducted from the year 2006 to 2015 wherein all the patients diagnosed with PCL were identified. Complete clinical and treatment details and outcome were obtained from the records.Results: There were total 18 cases of PCL (3.7% of cases with multiple myeloma) diagnosed between the year 2006 and 2015. 16 cases (84%) were primary PCL, and two cases were secondary PCL. Twelve patients were males and six were females. The median age was 56.5 years. All patients had aggressive clinical course and median overall survival even with immunomodulatory agents was only 3 months.Conclusion: PCL is a very aggressive disease, and no prospective trials have been conducted. Patients with PCL require induction with immunomodulators, proteasome inhibitors, and further trials are needed to evaluate the role of autologous stem cell transplant in this disease. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
42. Brachystelma vemanae (Apocynaceae–Asclepiadoideae), a new species with completely reflexed corolla lobes and solitary flowers from Eastern Ghats, Andhra Pradesh, India.
- Author
-
Reddy, A. Madhusudhana, Suresh Babu, M. V., Nagendra, C., Gangadhar, P., and Prasad, K.
- Subjects
- *
BRACHYSTELMA , *PLANT classification , *PHYTOGEOGRAPHY , *PLANT morphology , *BOTANICAL specimens - Abstract
Brachystelma vemanae, a new species of Apocynaceae, is described and illustrated. The relationships of new species to other known taxa of the genus from India are discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
43. Synthesis of aromatic aldehydes via NiCl 2 reduction and hydrolysis of oxazolines
- Author
-
Suresh Babu, M. and Lokanatha Rai, K.M.
- Published
- 2004
- Full Text
- View/download PDF
44. T-Cell Prolymphocytic Leukemia: An Experience From A Tertiary Cancer Centre In South India.
- Author
-
SURESH BABU, M. C., LAKSHMAIAH, KUNTEGOWDANAHALLI C., and GOVIND BABU, K.
- Subjects
- *
STEM cell transplantation , *LYMPHOCYTE count , *LEUKOCYTE count , *STEM cell treatment , *LEUKEMIA - Abstract
Background - T-cell prolymphocytic leukemia (T-PLL) is a rare lymphoid malignancy with dismal prognosis. Most patients have increased lymphocyte count (>1, 00, 000/dL) and widespread disease at presentation. Despite high response rate seen with alemtuzumab, the disease relapse is inevitable. Methods - This was a retrospective observational study done at a tertiary cancer centre in South India. All patients diagnosed with T-PLL from August 2010 to July 2015 were studied for the clinical characteristics, pathological findings and treatment outcomes. Results - Seven patients were diagnosed as T-PLL over a period of 5 years. The median age at diagnosis was 51 years. In the present series, 6 patients (86%) had splenomegaly and 3 had hepatomegaly (43%). Generalized lymphadenopathy was seen in 4 (57%) patients at presentation. Skin lesions were seen in 5 (71%) patients whereas pleural effusion in only one patient (14%). All had elevated total leukocyte count, with more than 1, 00, 000/ dL in 4 patients. The median survival was 5 months with different chemotherapy (CT) regimens (5 received CT and 2 patients on best supportive care). Conclusion - T-PLL is a rare diagnosis with no definite treatment guidelines. Treatment with alemtuzumab and stem cell transplant have the best outcome at present, but invariably the disease relapse. [ABSTRACT FROM AUTHOR]
- Published
- 2017
45. Retinitis Pigmentosa.
- Author
-
Suresh Babu, M., Venkatesh, C. R., Kiran, P. K., Kumar, S. Sunil, and Reddy, K. Prabhath Kiran
- Subjects
- *
RETINAL degeneration , *RETINITIS pigmentosa - Abstract
The article provides an answer to a question of bilateral inherited progressive retinal degeneration disease called retinitis pigmentosa (RP).
- Published
- 2015
46. Synthesis of aromatic aldehydes via NiCl2 reduction and hydrolysis of oxazolines
- Author
-
Suresh Babu, M. and Lokanatha Rai, K.M.
- Published
- 2004
- Full Text
- View/download PDF
47. Nutrition in children with cerebral palsy.
- Author
-
Suresh-Babu, Mirajkar V., Thomas, Adrian G., Braegger, Christian, Büller, Hans, Thomas, Adrian, Bishop, Warren P., Haber, Barbara Anne, Lichtman, Steven N., Shneider, Benjamin L., Suresh-Babu, M V, and Thomas, A G
- Published
- 1998
48. Clinicoradiological findings in a case of cleidocranial dysplasia.
- Author
-
Shahri D, Suresh Babu M, Lakkur Siddappa A, and Swathi BS
- Subjects
- Humans, Male, Tomography, X-Ray Computed, Cleidocranial Dysplasia diagnostic imaging
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2024
- Full Text
- View/download PDF
49. Discordance in clinical versus pathological staging in breast cancer: Are we undermining the significance of accurate preoperative staging in the present era?
- Author
-
Goyal S, Jacob LA, Lokanatha D, Suresh Babu MC, Lokesh KN, Rudresha AH, Saldanha S, Amirtham U, Thottian AGF, and Rajeev LK
- Subjects
- Adult, Aged, Aged, 80 and over, Breast Neoplasms secondary, Disease-Free Survival, Female, Humans, Mammography, Medical Records, Middle Aged, Prognosis, Retrospective Studies, Young Adult, Breast Neoplasms classification, Breast Neoplasms diagnostic imaging, Neoplasm Staging methods, Neoplasm Staging standards
- Abstract
Background: The present era of individualized treatment for breast cancer is influenced by the initial disease status including the anatomical extent, grade, and receptor status. An accurate preoperative staging is the basis of treatment planning and prognostication. Our study aims to determine the discordance between the preoperative clinical and the postoperative pathological stages of breast cancer patients., Methodology: The medical records of all non-metastatic breast cancer patients from January 2017 to December 2018 who underwent upfront surgery were reviewed. They were staged as per the eighth AJCC and the concordance between the clinical (c) and pathological T (tumor), N (nodal), and final AJCC stage was studied. A Chi-square test was used to determine factors that significantly correlate with disease discordance., Results: A total of 307 breast cancer patients were analyzed. Among these, 43.3% were hormone receptor-positive, 30.6% were Her2 positive and 26% were triple-negative. Overall stage discordance was seen in 48.5% (n = 149) patients (upstaging in 22.1%, downstaging in 26.4%). The discordance rate was 48.9% for T stage (cT versus pT) and 57.4% for N stage (cN versus pN). Among patients with clinically node-negative disease, 53.4% were found to have positive nodes on histopathology, while 27.2% had vice versa. Overall, the factors associated with upstaging were ER-positive, Her2 positive and triple-negative status (all p < 0.05), while none of the factors showed significant association with downstaging., Conclusions: About half of breast cancer patients had discordance between clinical and pathological staging with higher discordance in the nodal stage. This changes the disease prognosis, and may also affect the offered surgical treatment and radiotherapy. Thus highlighting the need for a precise pre-operative staging. Also, this information will aid clinicians in discussions with patients, keeping in mind the likelihood of change in disease staging and management.
- Published
- 2022
- Full Text
- View/download PDF
50. Socioeconomic and administrative factors associated with treatment delay of esophageal and gastric carcinoma: Prospective study from a tertiary care centre in a developing country.
- Author
-
Lokanatha D, Hassan SA, Jacob LA, Suresh Babu MC, Lokesh KN, Rudresha AH, Rajeev LK, Saldanha S, and Thottian AGF
- Subjects
- Adult, Aged, Aged, 80 and over, Developing Countries, Esophageal Neoplasms pathology, Female, Humans, Male, Middle Aged, Prognosis, Prospective Studies, Stomach Neoplasms pathology, Tertiary Care Centers, Esophageal Neoplasms epidemiology, Socioeconomic Factors, Stomach Neoplasms epidemiology, Time-to-Treatment standards
- Abstract
This study was aimed to analyze the spectrum of time intervals, from the onset of symptoms to the commencement of treatment in esophagogastric cancers. Factors influencing these time delays and correlation between these time points with variables including socioeconomic strata, educational level, histopathology, location of tumor and the initial modality of treatment were assessed., Study Setting and Methods: A prospective analysis of patients with esophagogastric cancer presenting to a single tertiary care unit over a period of 12 months was performed. Histopathology other than adenocarcinoma and squamous cell were excluded., Results: 202 patients were enrolled in the study. Most patients presented with advanced disease, i.e. 91.5 % of esophageal and 90 % of gastric malignancies belonged to either stage 3 or stage 4 as per American Joint Committee on Cancer (AJCC) tumor-node-metastasis (TNM) staging system. The median delay from the appearance of the first symptoms to initiation of treatment was 15 weeks (range 4-64). Patient related factors contributed to a significant delay [median of 5 weeks (range 1-24)]. Administrative factors were responsible for median delay of 3 weeks (range 0.5-20). Curative multimodality treatment was administered in 62.5 % of patients. Significant longer delay was influenced by socioeconomic strata, educational level, evaluation by non-specialist (p < 0.05). No relationship was noted between histopathology, location of tumor or initial modality of treatment., Conclusions: Delays in our setting is much more than that is seen in Western and even some Asian countries. An important component of delay is administrative related factors. These may be intervened at the hospital level compared to other factors which may need long term community oriented approaches., Competing Interests: Declaration of Competing Interest On behalf of all the contributors I hereby declare that there are no conflict of interest., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.